Health UnaBASHEd: From the BIO 2026 Floor: A Deep Dive into Rare Disease Innovation

Recorded live from BIO 2026 in San Diego, Gil captures a conversation with Craig Martin, Founder and CEO of Orphan Therapeutics Accelerator and Amber Freed, Founder & CEO of the Non-profit, SLC6A1 Connect that is equal parts heartbreak, science, economics, and stubborn optimism. Gil engages two of the rare disease world's most energized advocates immediately following a panel they participated in together on ultra-rare diseases. What emerged was a wide-ranging discussion about the gap between breakthrough science and patient access, the systemic failures that leave life-saving molecules on a shelf, and the personal cost of building a movement from grief.